UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Nature communications, 2022-06, Vol.13 (1), p.3671-3671, Article 3671

2022

Volltextzugriff (PDF)

Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes

Cancers, 2024-05, Vol.16 (10), p.1879

2024

Volltextzugriff (PDF)

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Nature communications, 2022-11, Vol.13 (1), p.7140-7140, Article 7140

2022

Volltextzugriff (PDF)

Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PloS one, 2015-04, Vol.10 (4), p.e0126988-e0126988

2015

Volltextzugriff (PDF)

Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis

NPJ breast cancer, 2024-02, Vol.10 (1), p.17-17, Article 17

2024

Volltextzugriff (PDF)

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer

European journal of cancer (1990), 2022-11, Vol.175, p.169-179

2022

Volltextzugriff (PDF)

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

Biomarker Insights, 2016-01, Vol.2016 (11), p.139-146

2016

Volltextzugriff (PDF)

Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging

JCI insight, 2019-07, Vol.5 (14)

2019

Volltextzugriff (PDF)

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer

Breast cancer research : BCR, 2023-10, Vol.25 (1), p.1-117, Article 117

2023

Volltextzugriff (PDF)

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Frontiers in oncology, 2022-03, Vol.12, p.802579-802579

2022

Volltextzugriff (PDF)

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

JAMIA open, 2021-04, Vol.4 (2), p.ooab038-ooab038

2021

Volltextzugriff (PDF)

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

The Journal of molecular diagnostics : JMD, 2019-09, Vol.21 (5), p.808-823

2019

Volltextzugriff (PDF)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

NPJ breast cancer, 2022-12, Vol.8 (1), p.128-128, Article 128

2022

Volltextzugriff (PDF)

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL

Journal of medical imaging (Bellingham, Wash.), 2018-01, Vol.5 (1), p.011014-011014

2018

Volltextzugriff (PDF)

Abstract 3362: Factors driving industry participation in the collaborative I-SPY2 platform trial

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3362-3362

2019

Volltextzugriff (PDF)

Abstract P4-10-24: Cyclin E overexpression is associated with high risk 70 gene signature, and may indicate intrinsic resistance to CDK4/6 inhibitors

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-10-24

2020

Volltextzugriff (PDF)

Abstract P2-01-03: Elucidating the biology of circulating tumor DNA (ctDNA) shedding across receptor subtypes in high-risk early-stage breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-01-03

2022

Volltextzugriff (PDF)

Abstract PS11-01: Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS11-01-PS11-01

2021

Volltextzugriff (PDF)

Abstract GS4-11: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS4-11-GS4-11

2021

Volltextzugriff (PDF)

Abstract PS6-01: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS6-01-PS6-01

2021

Volltextzugriff (PDF)

Hard Wired Genotype in Metastatic Breast Cancer

Cell cycle (Georgetown, Tex.), 2004-06, Vol.3 (6), p.754-755

2004

Volltextzugriff (PDF)

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-10-02-OT1-10-02

2022

Volltextzugriff (PDF)

Abstract P1-21-08: Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-21-08

2020

Volltextzugriff (PDF)

Abstract P5-08-01: Breast cancer risk thresholds as a predictor of chemoprevention uptake in the Athena Breast Health Network

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P5-P5-08-01

2020

Volltextzugriff (PDF)

Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD8-07-PD8-07

2022

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(76)
Tagungsberichte
(1)

Sprache

Englisch
(77)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL

Abstract 3362: Factors driving industry participation in the collaborative I-SPY2 platform trial

Abstract P4-10-24: Cyclin E overexpression is associated with high risk 70 gene signature, and may indicate intrinsic resistance to CDK4/6 inhibitors

Abstract P2-01-03: Elucidating the biology of circulating tumor DNA (ctDNA) shedding across receptor subtypes in high-risk early-stage breast cancer

Abstract PS11-01: Outcome without adjuvant systemic treatment in breast cancer patients included in the MINDACT trial

Abstract GS4-11: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status

Abstract PS6-01: How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status

Hard Wired Genotype in Metastatic Breast Cancer

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer

Abstract P1-21-08: Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial

Abstract P5-08-01: Breast cancer risk thresholds as a predictor of chemoprevention uptake in the Athena Breast Health Network

Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Aktive Filter

Suchergebnisse filtern